Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir monohydrate is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - zopiclone, quantity: 7.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; purified talc; povidone; maize starch; sodium starch glycollate type a; hypromellose; lactose monohydrate; titanium dioxide; calcium hydrogen phosphate dihydrate; macrogol 6000 - short term treatment of insomnia 7 - 14 days.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - zopiclone, quantity: 7.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; purified talc; povidone; maize starch; sodium starch glycollate type a; hypromellose; lactose monohydrate; titanium dioxide; calcium hydrogen phosphate dihydrate; macrogol 6000 - short term treatment of insomnia (7 - 14 days)

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; hypromellose; titanium dioxide; purified talc; macrogol 6000 - entecavir sandoz is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; titanium dioxide; lactose monohydrate; crospovidone; magnesium stearate; microcrystalline cellulose; macrogol 6000; iron oxide red; iron oxide yellow - entecavir sandoz is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zopiclone, quantity: 7.5 mg - tablet, film coated - excipient ingredients: maize starch; purified talc; sodium starch glycollate type a; colloidal anhydrous silica; magnesium stearate; povidone; titanium dioxide; hypromellose; lactose monohydrate; macrogol 6000; calcium hydrogen phosphate dihydrate - short term treatment of insomnia (7 -14 days)

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - adefovir dipivoxil, quantity: 10 mg - tablet - excipient ingredients: pregelatinised maize starch; magnesium stearate; purified talc; croscarmellose sodium; lactose monohydrate - ? adefovir dipivoxil is indicated for the treatment of chronic hepatitis b in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease. ? for adult patients, this indication is based on histological, virological, biochemical, and serological responses in adult patients with hbeag+ and hbeag-/hbvdna+ chronic hepatitis b with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis b virus with either compensated or decompensated liver function. ? for adolescent patients (12 to <18 years of age), the indication is based on virological and biochemical responses in patients with hbeag+ chronic hepatitis b virus with compensated liver function.